Equity Overview
Price & Market Data
Price: $24.61
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $5,008,926,720
Daily Volume: 0
Performance Metrics
1 Week: 4.50%
1 Month: -7.69%
3 Months: -1.44%
6 Months: 45.62%
1 Year: 71.02%
YTD: -3.19%
Company Details
Employees: 362
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.